Exactus, Inc. (EXDI) - New Audited Fully Reporting Cannabis Company Under $2.00 That Could See Over $10 Soon
April 11 2019 - 9:00AM
InvestorsHub NewsWire
Exactus, Inc. (EXDI)
- New Audited Fully Reporting Cannabis Company Under $2.00 That
Could See Over $10 Soon
New York, NY -- April 11, 2019 --
InvestorsHub NewsWire -- www.nextbigticker.com -- Exactus, Inc. (OTCQB:
EXDI) is a new audited and fully reporting cannabis sector
company that has targeted the very lucrative CBD market with a
200-acer hemp farm as its first asset and a $1 million CBD order on
the books. EXDI has set out to make itself a leading brand
name recognized for top quality CBD. With industry estimates
ranging from $30,000 to $60,000 in CBD revenue per acre, EXDI could
realize $6 million to $12 million in sales this year. Some
analysts have estimated CBD revenue per acer even higher than the
$30,000 to $60,000 range.
Aurora Cannabis (NYSE:
ACB) CCO Cam Battley refers to cannabis stock valuation
potentials in hockey stick terms where early stage valuations are
on the blade, turning through an inflection point and then
rocketing up the stick. Even with audited and fully reporting
cannabis sector companies trading at 100 x P/E ratios, valuations
today are characterized in hockey stick terms as still being in the
blade or inflection point stages.
EXDI is yet undiscovered by the market
with relatively light trading volume and a recent PPS ranging from
$1.25 to $1.85. EXDI’s valuation in hockey stick terms is
still a blade opportunity. The EXDI valuation will enter the
inflection stage this year as it signs more orders in addition to
its first $1 million order for CBD to be produced from its 200-acre
hemp farm. As more orders come in validating EXDI’s $6
million to $12 million first year revenue potential, the market is
likely to discover EXDI bringing liquidity and stabilizing PPS
volatility.
The legalization of recreational marijuana
in Canada has ushered Canadian Cannabis Sector Companies into the
hockey stick inflection stage of growth. US Cannabis Sector
Companies focused on the CBD sector will begin entering the
inflection stage his year as US States begin to adopt the 2018 Farm
Act legalization of hemp
farming.
EXDI $2.00 to $10.00 PPS
Potential
With the high margin potential of CBD
production from hemp farming and the cannabis sector inflection
point P/E ratios currently accepted by the market, EXDI has the
potential to see a substantial PPS increase this year. If
EXDI can demonstrate the potential for producing a $3 million net
income by signing additional CBD orders and demonstrating
reasonable yield management evidenced in its quarterly reports, the
PPS has the potential to reach $5.00 if it only modestly enjoys the
current cannabis sector P/E ratios seen in the market today.
A more optimistic, but still relatively conservative realization of
prevailing cannabis sector valuations could see EXDI reach a $10.00
PPS by year end.
EXDI has an experienced and proven
management team that brings both cannabis sector experience and a
broad and deep range of experience in health sciences - which
should provide a good idea about the direction the management team
plans to take their CBD product. The CEO, Philip Young has
served as President, Chief Executive Officer and Director for
AmpliPhi Biosciences, a global biopharmaceutical company. Before
that, he was the President, CEO and Director of Osteologix, Inc.
Prior to joining Osteologix, Mr. Young served as an Executive Vice
President and Chief Business Officer for Insmed Inc., a publicly
traded biotechnology company. Prior to Insmed Inc., Mr. Young held
executive positions at Elan, Neurex, and Pharmacia Corporations.
Mr. Young started his management career in the biopharmaceutical
industry at Genentech Inc. where he was responsible for their
cardiovascular and endocrine product launches sales and
marketing.
EXDI Berkshire Hathaway ROI
Potential
With Mr. Young’s experience and the
experience of the rest of the executive team, EXDI has the look of being a serious
US Cannabis Sector contender. An investment in EXDI stock
under $2.00 could produce an exciting cannabis sector ROI of over
100% and perhaps as high as 500% this year if the company performs
on what is publicly disclosed and realizes a PPS of $5.00 to
$10.00. With the caliber of the management team that has come
together at EXDI and the investment that has been made in building
the company as an audited and fully reporting company, it is fair
to speculate that the company probably has bigger plans that have
not yet been disclosed – perhaps a up-listing to NASDAQ and some
substantial M&A activity is in the works. With the
inclusion of possibly yet unknown aspects of the business plan in
the works, an EXDI investment today under $2.00 could produce
Berkshire Hathaway returns.
Learn more about EXDI at https://www.exactusinc.com/
A robust cannabis sector investment
portfolio should include a combination of fast-moving penny and sub
penny priced stocks that can produce multiples in days or weeks
when a company signs a new contract, or transacts some other major
milestone. That robust cannabis sector investment portfolio
also needs to include one or two diligent, longer-term reaching
companies like EXDI that could produce life changing wealth.
Look for fast returns from companies such as Puration, Inc.
(USOTC:
PURA), North American Cannabis Holdings, Inc. (USOTC:
USMJ) and Hemp, Inc. (USOTC: HEMP) and then add an EXDI to your
portfolio.
DISCLAIMER: NextBigTicker.com (NBT)is
a third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com